Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.60 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21580130 | 0.99 | NAMPT (0.59) | NAMPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23691873 | 0.86 | NAMPT (0.47) | NAMPTPARP15PARP10 | |
| SCHEMBL21580147 | 0.79 | NAMPT (0.65) | NAMPTHDAC1 | |
| SCHEMBL21580047 | 0.78 | SSTR4 (0.44) | NAMPTPDE4D | |
| SCHEMBL28409528 | 0.78 | NAMPT (0.64) | NAMPTHDAC1 | |
| SCHEMBL28410809 | 0.77 | NAMPT (0.60) | NAMPTHDAC1 | |
| SCHEMBL21580112 | 0.76 | NAMPT (0.52) | NAMPTHDAC1PARP15PARP10 | |
| SCHEMBL16108024 | 0.75 | NAMPT (1.00) | NAMPT | |
| Hydrochloric Acid SCHEMBL5241522 | 0.75 | PARP15 (0.57) | PDE4APDE4BPDE4CPDE4DSRC | |
| SCHEMBL15246208 | 0.74 | NAMPT (0.68) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| WO-2019218024-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2019-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, TRPV3 | NAMPT 1188/4885PDE4A 340/4885PDE4B 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.